Catalyst Wire Dossier Catalyst Wire Dossier

Afatinib (Gilotrif)

afatinib · Boehringer Ingelheim
Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for Afatinib (Gilotrif), covering 2017-04-12 to 2025-07-17. Get the full timeline:

Most recent: Clinical Trial Update: Afatinib Combined With Chemotherapy as Conversion Therapy in Unresectable EGFR Sensitive Mutation-positive Stage III NSCLC [Phase 2]

See pricing